Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) on Tuesday announced positive topline results from the Phase 3 MARIPOSA study, demonstrating that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) significantly improved overall survival (OS) compared to osimertinib as a first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
This is the first and only regimen to show a survival benefit over the current standard of care in this setting. The median OS improvement is expected to exceed one year.
The MARIPOSA study evaluated RYBREVANT plus LAZCLUZE in 1,074 patients. OS was a key secondary endpoint, and these results build upon previously reported positive data on progression-free survival. J&J noted that the safety profile of the combination was generally consistent with the individual treatments.
These OS results will be presented at an upcoming major medical meeting and shared with global health authorities.
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas